| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 69.08 | 45347 |
| Intrinsic value (DCF) | 0.20 | 32 |
| Graham-Dodd Method | 0.07 | -53 |
| Graham Formula | 0.80 | 428 |
IntegraGen SA, a subsidiary of OncoDNA SA, is a French biotechnology company specializing in human genome analysis services for academic researchers and life sciences companies. Founded in 2000 and headquartered in Évry, France, IntegraGen provides a comprehensive suite of genomic services, including transcriptomics, epigenomics, DNA sequencing, and NGS testing for cancer research. The company also offers clinical research services, agrigenomics, and microbial genomics, catering to diverse sectors within healthcare and life sciences. IntegraGen's proprietary tools, such as MERCURY, SIRIUS, Galileo, and GeCo, enhance its service offerings by providing advanced bioinformatics solutions for data interpretation and analysis. Operating in the competitive biotechnology sector, IntegraGen focuses on translational and clinical research, positioning itself as a key player in genomic services in France. With a market capitalization of approximately €4.19 million, the company continues to innovate in precision medicine and genomic research, despite financial challenges.
IntegraGen SA presents a niche investment opportunity in the genomic services sector, with specialized offerings in cancer research and bioinformatics. However, the company's financials reveal significant risks, including a net loss of €256,000 in the latest fiscal year and negative diluted EPS of -€0.038. While its revenue of €8.7 million indicates operational activity, the lack of positive operating cash flow and minimal cash reserves (€1.9 million) raise liquidity concerns. The company's low beta (0.162) suggests limited correlation with broader market movements, which may appeal to risk-averse investors seeking exposure to biotechnology. Nonetheless, IntegraGen's small market cap and dependence on the competitive genomics market warrant caution. Potential investors should closely monitor its ability to achieve profitability and expand its client base in academic and clinical research.
IntegraGen SA operates in a highly competitive biotechnology and genomics market, where larger players dominate with broader service portfolios and global reach. The company's competitive advantage lies in its specialized focus on oncology and translational research, supported by proprietary bioinformatics tools like MERCURY and SIRIUS. These tools differentiate IntegraGen by enabling advanced data interpretation, which is critical for clinical and academic researchers. However, the company's small scale and regional focus in France limit its ability to compete with multinational genomics firms. IntegraGen's subsidiary status under OncoDNA SA provides some strategic support but may also constrain independent growth opportunities. The company's reliance on the French market exposes it to regional economic and regulatory risks, whereas competitors benefit from diversified geographic operations. To strengthen its position, IntegraGen must expand its technological capabilities and forge partnerships with larger healthcare and biotech entities. Its current financial instability further hampers competitive positioning, making it vulnerable to consolidation or acquisition by larger industry players.